"$2B / 5 equals avg of 400M per year. Apply that with a PE of 10 gives a market cap 4B."
That is indeed one conservative PE ratio - the average for the biotech industry on the ASX is 46 which on the 'lower side' of that average is CSL with a PE of 37, so that's your conservative base case. For contrast, Telix has a PE of 124. Pretty much pick any number well north of 50 for the PE for any ASX biotech that gets their first drug to market.
"$2B / 5 equals avg of 400M per year. Apply that with a PE of 10...
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
59.5¢ |
Change
-0.015(2.46%) |
Mkt cap ! $732.5M | |||
| Open | High | Low | Value | Volume |
| 60.0¢ | 61.0¢ | 59.0¢ | $11.30M | 18.98M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 45916 | 59.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 60.0¢ | 10000 | 1 |
View Market Depth
| Last trade - 16.10pm 11/09/2024 (20 minute delay) ? |
| OPT (ASX) Chart |